(r)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl)-benzoic acid as ep4 receptor antagonist
EP3735974A1
Use of 2-phenyl-6-(1h-imidazol-1-yl)quinazoline for treating neurodegenerative diseases, preferably alzheimer's disease
EP3725777A1
Benzo- and pyrido-pyrazoles as protein kinase inhibitors
WO2020207570A1
Phenazines as inhibitors of discoidin domain receptors 2 (ddr2)
EP3722319A1
Pharmaceutical combination of an ep4 antagonist and immune checkpoint inhibitors for the treatment of tumours
WO2016020854A1
Purified cocoa beans extracts, production and use thereof for the treatment of central and peripheric human diseases
WO2016020855A1
Purified grape seeds extracts, production and use thereof for the treatment of central and peripheric human diseases
WO2016020853A1
Purified cocoa beans and grape seeds extracts, production and use thereof for the treatment of central and peripheric human diseases
EP3070084A1
New fyn kinase inhibitors
CA2866410A1
Chemical compounds
US2015051226A1
4,4-difluoro-piperidine-compounds
US2014357653A1
Chemical compounds
EP2674439A1
Anti-TrkA antibodies, derivatives and uses thereof
EP2650310A1
Anti-ADAMTS-5 antibody, derivatives and uses thereof
EP2614050A1
1,5-diaryl-2-alkylpyrrole-3-substituted nitro esters, selective cox-2 inhibitors and nitric oxide donors
EP2729141A1
Cyclic amine derivatives as ep4 receptor agonists
AU2010255376A1
Crystalline forms of 6-(1H- imadazol- 1-yl) -2-phenylquinazoline
EP2190829A2
Amidine, thiourea and guanidine derivatives of 2-aminobenzothiazoles and aminobenzothiazines for their use as pharmacological agents for the treatment of neurodegenerative pathologies
EP2059504A1
3-substituted-1,5-diarly-2-alkyl-pyrroles highly selective and orally effective cox-2 inhibitors
AU2005200915A1
Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production
